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ABSTRACT
Leveraging population-distinct linkage equilibrium (LD) patterns, trans-ethnic 
follow-up of variants discovered from genome-wide association studies (GWAS) has 
proved to be useful in facilitating the identification of bona fide causal variants. We 
previously developed the preferential LD approach, a novel method that successfully 
identified causal variants driving the GWAS signals within European-descent 
populations even when the causal variants were only weakly linked with the GWAS-
discovered variants. To evaluate the performance of our approach in a trans-ethnic 
setting, we applied it to follow up breast cancer GWAS hits identified mostly from 
populations of European ancestry in African Americans (AA). We evaluated 74 breast 
cancer GWAS variants in 8,315 AA women from the African American Breast Cancer 
Epidemiology and Risk (AMBER) consortium. Only 27% of them were associated 
with breast cancer risk at significance level α=0.05, suggesting race-specificity of 
the identified breast cancer risk loci. We followed up on those replicated GWAS hits 
in the AMBER consortium utilizing the preferential LD approach, to search for causal 
variants or better breast cancer markers from the 1000 Genomes variant catalog. Our 
approach identified stronger breast cancer markers for 80% of the GWAS hits with 
at least nominal breast cancer association, and in 81% of these cases, the marker 
identified was among the top 10 of all 1000 Genomes variants in the corresponding 
locus. The results support trans-ethnic application of the preferential LD approach 
in search for candidate causal variants, and may have implications for future genetic 
research of breast cancer in AA women.
INTRODUCTION
Genome-wide association studies (GWAS) premised 
on the “common disease, common variants” hypothesis 
have made great strides in identifying common genetic 
variants associated with a variety of phenotypes [1]. 
Typically, the GWAS-identified variants for any particular 
phenotype cumulatively explain only a small portion of the 
phenotypic variation [2]. One explanation for the so-called 
missing heritability problem is that the variants identified 
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by GWAS are often only proxies of the causal variants that 
still remain to be discovered [3, 4]. The association signal 
attenuates as the linkage disequilibrium (LD) between 
the causal variant(s) and the GWAS-discovered variant 
decreases, particularly when the causal variant(s) are rare 
in the population. Until recently, the majority of GWAS 
have focused on populations of European descent, where 
the causal variants can be far from the associated marker 
due to strong LD, making it difficult to localize the causal 
variants [5, 6]. Thus, trans-ethnic follow-up studies in 
populations with lower LD are becoming more common 
[7–13]. Studies in populations with lower average LD 
often yield shorter distances between causal variants and 
the associated marker, helping to narrow down the causal 
variants underlying the disease associations [5, 14].
We previously developed the novel preferential LD 
approach to identify causal variants that drive the GWAS 
signal of interest from a comprehensive genome-wide 
variant catalog [15]. This approach is premised on the 
notion that the LD between the causal variant(s) and the 
GWAS-discovered variant is stronger than the LD between 
the causal variant(s) and most other variants interrogated 
in the GWAS, even if the causal variants are rare and 
only weakly linked to the GWAS-discovered variant. The 
increasing number of publications where causal variants 
are in only weak LD with the GWAS hits emphasizes the 
need for approaches beyond the absolute magnitude of 
the LD [16–29]. Our approach selects candidate causal 
variants at the locus of the GWAS-discovered variant 
from the variant catalog and prioritizes them based on the 
tagging specificity of the candidate variants by the GWAS-
discovered variant, as well as functional importance 
of the candidate variants. We showed that the approach 
could successfully pinpoint the known causal variants of 
diverse traits when the discovery population and follow-
up population were from the same ethnic group [15]. We 
anticipated that the preferential LD approach would also 
perform well in a trans-ethnic setting, which leverages 
the benefit of shorter LD structure. As the preferential LD 
approach does not rely on any phenotypic information, 
another advantage of the approach is its ability to 
follow up GWAS of various phenotypes using the same 
comprehensive variant catalog, such as the 1000 Genomes 
project [30, 31] or other large-scale sequencing efforts. 
This feature allows the approach to make the most use of 
the rapidly accumulating variant data from next-generation 
sequencing.
In this study, we evaluated the performance of the 
preferential LD approach in an African American (AA) 
population, following up breast cancer GWAS hits. We 
carried out the study in the African American Breast 
Cancer Epidemiology and Risk (AMBER) consortium, 
which provides rich genetic and epidemiological resources 
for investigating breast cancer risk in AA women [32–
36]. To date, a large number of GWAS and ensuing 
meta-analyses have been performed on breast cancer 
susceptibility, with more than 90 loci meeting the stringent 
criteria of genome-wide significance level identified [37–
39]. However these GWAS were predominantly performed 
in European populations, with only two conducted among 
individuals of African ancestry [40, 41]. Even in the well-
studied European populations, collectively, the GWAS-
discovered variants only account for an estimated 16% 
of breast cancer heritability [39]. The large missing 
heritability emphasizes the need to pinpoint causal variants 
or better markers of breast cancer.
We first sought to evaluate the 74 GWAS-identified 
breast cancer risk variants (Supplementary Table S1) in 
8,315 AA women (3,648 cases, including 1,977 ER+ 
cases and 1,092 ER- cases, and 4,667 controls) from the 
AMBER consortium [34–36]. We then followed up those 
GWAS signals that were replicated in AAs by utilizing 
the preferential LD approach and the comprehensive 
variant catalog of African population from 1000 Genomes 
Project, to search for candidate causal variants or better 
breast cancer markers in an AA population. The variants 
selected by the preferential LD approach were genotyped 
in the AMBER consortium and then compared with all 
neighboring 1000 Genomes variants in evaluation of the 
approach’s performance in a trans-ethnic setting.
RESULTS
Replication of GWAS-discovered variants in AA 
women from the AMBER consortium
Out of the 74 GWAS-discovered variants, only 18 
were associated with overall breast cancer risk in AMBER 
with nominal p-value < 0.05 (Table 1). All of them had 
association directions consistent with previous reports. 
The replication rate was higher for the variants discovered 
initially in populations of African ancestry [53] (4/7 
or 57.1%) than those discovered in populations of non-
African ancestry (14/67 or 20.9%).
Of the 74 GWAS-discovered variants, eight and 
fifteen have been reported to be associated with ER+ and 
ER- breast cancer, respectively [53–58] (Supplementary 
Table S2). We then tested the association of these 
particular variants with the corresponding breast cancer 
subtypes. Four of the eight GWAS-discovered ER+ breast 
cancer variants were found to affect ER+ breast cancer 
risk in the AMBER Consortium (nominal p-value < 
0.05), including rs3112572 at chromosome 16q12, which 
was not replicated when tested for overall cancer risk 
(Table 1). For ER- breast cancer, five of the fifteen GWAS-
discovered ER- breast cancer variants were associated, 
including rs4245739 at chromosome 1q32, which was 
not associated with overall breast cancer risk (Table 1). 
Taking into account these additional replicated loci by ER 
status, the replication rate increased to 27.0% (20/74) for 
all variants, and 71.4% (5/7) and 22.4% (15/67) for the 
variants discovered in populations of African and non-
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African ancestry, respectively. These observations are 
consistent with the notion that it is increasingly difficult 
to replicate GWAS findings across populations as the 
replication population becomes more genetically distant 
from the GWAS population.
Dissecting the replicated GWAS signals
We next used the preferential LD approach to search 
for nearby (±500 kb) candidate causal variants or better 
markers with lower association p-values for the 20 GWAS-
Table 1: Replicated GWAS-discovered variants in AMBER imputation data
GWAS-discovered 
Variants
Region Neighboring Genes GWAS 
Population
Risk 
allele
RAFa Imputation 
Qualityb
OR p-valuec
Overall breast cancer risk
rs4849887 2q14.2 LOC84931, GLI2 European ancestry C 0.7124 0.9967 1.1086 6.85E-03
rs13000023 2q35 TNP1, DIRC3 African American G 0.8480 1.0079 1.1787 6.13E-04
rs16857609 2q35 DIRC3 European ancestry T 0.2483 1.0099 1.1196 4.16E-03
rs13387042 2q35 TNP1, DIRC3 European ancestry A 0.7291 1.0121 1.0841 0.0365
rs10069690 5p15.33 TERT European ancestry T 0.5955 1.0237 1.1107 2.40E-03
rs1432679 5q33.3 EBF1 European ancestry C 0.7989 1.0163 1.1373 2.58E-03
rs9693444 8p12 DUSP4, LINC00589 European ancestry A 0.3833 0.9835 1.0781 0.0339
rs1011970 9p21.3 CDKN2B-AS1 European ancestry T 0.3312 1.0244 1.0740 0.0473
rs2981578 10q26 FGFR2 African American C 0.8542 1.001 1.2520 4.99E-06
rs2981579 10q26.13 FGFR2 European ancestry A 0.6069 1.0172 1.1187 1.30E-03
rs1219648 10q26.13 FGFR2 European ancestry G 0.4286 1.0068 1.0766 0.0324
rs2981582 10q26.13 FGFR2 European ancestry A 0.4802 1.0005 1.0716 0.0438
rs3817198 11p15.5 LSP1 European ancestry C 0.1651 0.9933 1.0962 0.0472
rs609275 11q13 MYEOV, CCND1 African American C 0.5751 1.0104 1.1513 1.22E-04
rs6504950 17q22 STXBP4 European ancestry G 0.6551 1.0166 1.0743 0.0452
rs3745185 19p13 BABAM1 African American G 0.7775 1.0119 1.1853 3.85E-05
rs2363956 19p13.11 ANKLE1 European ancestry T 0.5136 1.0042 1.1365 1.92E-04
rs8170 19p13.11 BABAM1 European ancestry A 0.1993 1.0066 1.1465 1.36E-03
ER+ breast cancer risk
rs13387042 2q35 TNP1, DIRC3 European ancestry A 0.7272 1.0028 1.1077 0.0287
rs2981579 10q26.13 FGFR2 European ancestry A 0.6021 1.0196 1.1004 0.0224
rs3112572 16q12 LOC643714 African American A 0.2151 0.9970 1.1447 6.45E-03
rs3745185 19p13 BABAM1 African American G 0.7705 1.0119 1.1375 8.84E-03
ER– breast cancer risk
rs8170 19p13.11 BABAM1 European ancestry A 0.1943 0.9951 1.1866 8.38E-03
rs2363956 19p13.11 ANKLE1 European ancestry T 0.5069 1.0014 1.1823 1.44E-03
rs4245739 1q32.1 MDM4 European ancestry C 0.2405 1.0135 1.1490 0.0198
rs10069690 5p15.33 TERT European ancestry T 0.5972 1.0313 1.3217 2.47E-07
rs1432679 5q33.3 EBF1 European ancestry C 0.7956 1.0240 1.2758 2.92E-04
a: risk allele frequency in AMBER imputation data.
b: the information metric from IMPUTE2.
c: the p-values were based on logistic regression between variant genotypes and breast cancer status while controlling for 
other covariates (see Methods).
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discovered variants replicated in the AMBER consortium. 
A total of 5,451 candidates were identified by our approach 
from 127,697 variants in the 1000 Genomes variant 
catalog that lie within 500 kb of the GWAS-discovered 
variants (0.29−0.85 candidates per 1 kb for each GWAS-
discovered variant). Among these, 77,608 of the 1000 
Genomes variants including 4,932 of the preferential 
LD selected candidates were successfully genotyped 
or imputed in the AMBER consortium and were tested 
for association with breast cancer risk. After accounting 
for the pairwise correlations among these variants, the 
effective number of independent tests was 19,617 [59]. 
Using a Bonferroni correction for the effective number 
of independent tests, we required a significance level of 
2.55 x 10-6 to reach study-wide significance. We compared 
the candidate variants selected by our approach with all 
1000 Genomes variants to evaluate the performance of 
the preferential LD approach for association with breast 
cancer risk.
We first focused on the 18 loci where the GWAS-
discovered variants were associated with overall breast 
cancer risk in the AMBER consortium (Table 2). In 
general, we observed that markers with lower p-values are 
more enriched among the candidate variants selected by 
the preferential LD approach than among all neighboring 
1000 Genomes variants (Figure 1). Four variants 
passed the study-wide significance cutoff: rs73731716 
(p=1.33×10-6) in TERT locus and three variants in 
ANKLE1-BABAM1 locus, rs11668840, rs8100241, 
and rs12982058 (p=1.51×10-6, 2.29×10-6, and 2.33×10-
6 respectively) (Table 3 and Figure 2). All four variants 
except rs8100241 were selected by the preferential LD 
approach. In the ANKLE1-BABAM1 locus, variants 
rs8100241 and rs12982058 were no longer significant 
after conditioning on rs11668840 (p=0.7897 and 0.7954 
respectively), suggesting the three variants represent the 
same signal. Previously, Chen et al found rs11668840 to 
be the strongest signal in this locus only for ER- breast 
cancer in AAs. For overall breast cancer risk in AAs, 
rs3745185, instead, was the most significant variant in 
this locus [53]. In the AMBER consortium, we found 
rs11668840 to be the most significant variant associated 
with both overall breast cancer and ER- breast cancer. 
For 14 of the 18 loci, the preferential LD approach was 
able to identify a better marker with a more significant 
p-value than the GWAS-discovered variant. Furthermore, 
for seven loci, the preferential LD approach was able 
to select the best marker with the lowest association 
p-value among all neighboring 1000 Genomes variants. 
In contrast, the best marker can only be found in one locus 
if selecting fine-mapping variants based on high LD with 
the GWAS signals (r2>0.6). For an additional six loci, the 
best candidate identified by the preferential LD approach 
was among the top 10 best markers in the corresponding 
locus. It is worth noting that for 11 of the above 13 loci, 
the best candidates identified by this approach were only 
in weak LD (r2<0.6) with the GWAS-discovered variants, 
which demonstrates the ability of this approach to pinpoint 
candidates even when they were not strongly linked with 
the GWAS-discovered variants. For example, rs73731716, 
the best marker identified by preferential LD approach by 
following up the GWAS signal rs10069690, is also the best 
marker among the 6,912 tested 1000 Genomes variants at 
the surrounding TERT locus. It is significantly associated 
with overall breast cancer risk with p-value 1.33×10-6 but 
only has weak LD with the GWAS signal (r2=0.015).
We next investigated the 9 loci where the GWAS-
discovered variants were associated with breast cancer 
by ER status in the AMBER consortium (Table 2). The 
association between ER+ breast cancer and two variants in 
the neighborhood of GWAS-discovered variant rs3112572, 
rs1112135 and rs4238750, passed study-wide significance 
(Table 3 and Figure 3). These two variants were not 
included in the preferential LD candidates because they 
are more common than the GWAS-discovered variant 
rs3112572 in the 1000 Genomes African population (see 
Method). We will loosen up this requirement in future 
trans-ethnic applications of the preferential LD approach, 
as the allele frequencies can change substantially when 
the follow-up population is not the same as the GWAS 
population. In two replicated ER+ breast cancer loci, the 
best candidates identified by the preferential LD approach 
were among the top 10 best markers (Table 2). These 
include rs2912778 (p=1.22×10-5, ranked no.2 among 6438 
tested 1000 Genomes variants) for the locus surrounding 
GWAS signal rs2981579 (p=0.0224), and rs56269701 
(p=3.51×10-5, ranked no.1 among 6005 tested 1000 
Genomes variants) for the locus surrounding GWAS signal 
rs13387042 (p=0.0287). The association between ER- 
breast cancer and seven 1000 Genomes variants passed 
study-wide significance, including the GWAS-discovered 
variant rs10069690 and six variants in ANKLE1-BABAM1 
locus (Table 3). All six variants except rs8100241 were 
selected by the preferential LD approach but none were 
significant after conditioning on rs11668840. In four 
of the five replicated ER- breast cancer loci, the best 
candidates identified by the preferential LD approach were 
among the top 10 best markers (Table 2).
An example: dissecting a GWAS signal with 
known causal variant within FGFR2 locus in AA
FGFR2 locus was one of the first breast cancer 
loci identified by GWAS. The most strongly associated 
GWAS-variant is rs2981582, a non-coding variant in 
intron 2 of FGFR2, which encodes the fibroblast growth 
factor receptor 2 [7]. Further fine-mapping studies led to 
the identification of rs2981578 as the most likely causal 
variant in this locus [8, 60, 61]. The variant rs2981578 
resides in a FoxA1 binding site in an enhancer of FGFR2 
gene. The cancer risk allele (C) triggers stronger FoxA1 
and PolII binding, enhanced transcription activity, 
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Table 2: The performance of the preferential LD approach in identifying the best markers in the GWAS locia
GWAS-discovered 
Variants
Best marker in the 500kb 
neighborhood
Best marker among the preferential 
LD candidates
rsID p-value rsID Neighboring 
Genes
Imputation 
Quality
p-value r2,b rsID Neighboring 
Genes
Imputation 
Quality
p-value Rankc r2
Overall breast cancer risk
rs4849887 6.85E-03 rs4849899 LINC01101, 
GLI2
0.9967 5.64E-06 0.233 rs4849899 LINC01101, 
GLI2
0.9967 5.64E-06 1/5883 0.233
rs13000023 6.13E-04 rs185147777 DIRC3 0.8926 2.72E-04 0.012 rs113674867 LOC101928327, 
DIRC3-AS1
1.016 1.15E-03 10/6036 0.951
rs16857609 4.16E-03 rs185147777 DIRC3 0.8926 2.72E-04 0.001 rs78037304 DIRC3 1.001 6.13E-03 65/6178 0.054
rs13387042 0.0365 rs185147777 DIRC3 0.8926 2.72E-04 0.007 rs56269701 LOC101928327, 
DIRC3-AS1
1.0057 5.73E-04 2/6005 0.391
rs10069690 2.40E-03 rs73731716 TERT, 
MIR4457
0.9720 1.33E-06 0.015 rs73731716 TERT, 
MIR4457
0.972 1.33E-06 1/6912 0.015
rs1432679 2.58E-03 rs116197733LOC101927697, 
EBF1
0.6969 6.38E-04 0.01 rs60172775 EBF1 0.9998 4.48E-03 28/4844 0.821
rs9693444 0.0339 rs77271190 DUSP4, 
LINC00589
1.0115 3.99E-05 0.094 rs77271190 DUSP4, 
LINC00589
1.0115 3.99E-05 1/5446 0.094
rs1011970 0.0473 rs3731213 CDKN2A 1.0043 7.61E-04 0.031 rs143070667 CDKN2B-AS1 0.9993 1.22E-03 2/6241 0.026
rs2981578 4.99E-06 rs2912778 FGFR2 1.0095 3.75E-06 0.922 rs143014944 FGFR2 0.9821 7.46E-04 16/6444 0.025
rs2981579 1.30E-03 rs2912778 FGFR2 1.0095 3.75E-06 0.16 rs2912778 FGFR2 1.0095 3.75E-06 1/6438 0.160
rs1219648 0.0324 rs2912778 FGFR2 1.0095 3.75E-06 0.035 rs2912778 FGFR2 1.0095 3.75E-06 1/6422 0.035
rs2981582 0.0438 rs2912778 FGFR2 1.0095 3.75E-06 0.044 rs2912778 FGFR2 1.0095 3.75E-06 1/6432 0.044
rs3817198 0.0472 rs57936908 KRTAP5-5, 
FAM99A
0.9825 8.47E-04 0.003 rs74047514 MRPL23, 
MRPL23-AS1
0.9841 1.07E-02 31/6671 0.041
rs609275 1.22E-04 rs115894455 ORAOV1 0.9798 3.52E-05 0.011 rs625625 LINC01488, 
CCND1
1.0059 4.48E-05 4/5751 0.350
rs6504950 0.0452 rs16955774 STXBP4, HLF 1.0032 1.64E-03 0.003 rs114380381 STXBP4 0.9739 2.61E-02 44/4580 0.089
rs3745185 3.85E-05 rs11668840 ANKLE1, 
ABHD8
1.0679 1.51E-06 0.155 rs62126227 BABAM1 1.0081 4.64E-06 5/5593 0.781
rs2363956 1.92E-04 rs11668840 ANKLE1, 
ABHD8
1.0679 1.51E-06 0.519 rs11668840 ANKLE1, 
ABHD8
1.0679 1.51E-06 1/5558 0.519
rs8170 1.36E-03 rs11668840 ANKLE1, 
ABHD8
1.0679 1.51E-06 0.086 rs62126227 BABAM1 1.0081 4.64E-06 5/5572 0.034
ER+ breast cancer risk
rs13387042 0.0287 rs56269701 LOC101928327, 
DIRC3-AS1
1.0039 3.51E-05 0.391 rs56269701 LOC101928327, 
DIRC3-AS1
1.0039 3.51E-05 1/6005 0.391
rs2981579 0.0224 rs59100826 FGFR2, ATE1 0.9847 9.24E-06 0.001 rs2912778 FGFR2 1.0049 1.22E-05 2/6438 0.160
rs3112572 6.45E-03 rs1112135 CASC16 0.9996 7.75E-07 0.231 rs35850695 TOX3 0.9928 1.33E-05 11/5839 0.036
rs3745185 8.84E-03 rs10416082 PGLS 0.9055 7.96E-05 0.001 rs62126227 BABAM1 1.0092 1.11E-03 12/5593 0.781
ER– breast cancer risk
rs8170 8.38E-03 rs11668840 ANKLE1, 
ABHD8
1.0658 1.49E-07 0.086 rs62126227 BABAM1 1.0068 2.94E-04 11/5572 0.034
rs2363956 1.44E-03 rs11668840 ANKLE1, 
ABHD8
1.0658 1.49E-07 0.519 rs11668840 ANKLE1, 
ABHD8
1.0658 1.49E-07 1/5558 0.519
rs4245739 0.0198 rs12405987 LINC00628, 
PPP1R15B
0.9511 4.33E-04 0.005 rs12064622 PLEKHA6 0.9951 1.65E-03 4/5109 0.028
rs10069690 2.47E-07 rs10069690 TERT 1.0313 2.47E-07 1 rs6867141 TERT 0.9451 1.31E-05 2/6912 0.067
(Continued)
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and increased FGFR2 expression level [8, 60, 61]. The 
GWAS-discovered variant rs2981582, a tag of the causal 
variant, correlates with rs2981578 in European and Asian 
populations (r2=0.64 and 0.31 respectively), but the 
correlation is much lower in AAs (r2=0.05). Consistent 
with the LD, the association between rs2981582 and 
breast cancer risk is very strong in European individuals, 
more modest in Asian individuals, and mostly attenuated 
in AAs [8, 61]. In the AMBER Consortium, we also 
found rs2981582 was only nominally associated with 
overall breast cancer risk (p=0.0438). Nevertheless, 
rs2981578 was still the most likely causal variant of this 
locus in African-descent populations (p=4.99×10-6). After 
conditioning on the causal variant rs2981578, the major 
association signal in this locus was completely eliminated 
(Figure 4). The MAF for rs2981578 is much lower than 
the GWAS-discovered variant rs2981582 in the 1000 
Genomes AFR population (7.9% and 48.8% respectively). 
When using the preferential LD approach to follow up 
rs2981582, we assumed HapMap II variants from YRI 
Figure 1: The QQ plot of overall breast cancer association p-values in AMBER consortium. The variants selected by 
the preferential LD approach in the 18 replicated loci are in red. The 1000 Genomes variants in the same 18 loci are in black. The blue 
horizontal line corresponds to the study-wide significance cutoff 2.55×10-6.
GWAS-discovered 
Variants
Best marker in the 500kb 
neighborhood
Best marker among the preferential 
LD candidates
rsID p-value rsID Neighboring 
Genes
Imputation 
Quality
p-value r2,b rsID Neighboring 
Genes
Imputation 
Quality
p-value Rankc r2
rs1432679 2.92E-04 rs12332693 EBF1 1.0174 2.50E-04 0.919 rs60172775 EBF1 1.0043 5.92E-04 10/4844 0.821
a: the p-values were based on logistic regression between variant genotypes and breast cancer status while controlling for other covariates (see Methods).
b: calculated from the 1000 Genomes African population using Haploview.
c: the rank of the best marker identified by the preferential LD approach among all variants from the 1000 Genomes African population in the 500kb 
neighborhood of the GWAS-discovered variant.
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population (~2.9 M markers) as the genotyped variants 
in the original GWAS because the variants in the GWAS 
genotyping platform, an early SNP array at Perlegen 
Sciences with 266,732 variants, were not available (see 
Method). Although this assumption resulted in the removal 
of causal variant rs2981578 from the preferential LD 
candidates as it is a HapMAP variant in YRI population, 
our approach did identify rs2912778, which was most 
strongly associated with breast cancer in this locus in the 
AMBER consortium (p=3.75×10-6), as a candidate causal 
variant. Variant rs2912778 is also a non-coding variant 
in intron 2 of FGFR2 and it is highly correlated with the 
causal variant rs2981578 (r2=0.92, MAF= 8.5% in 1000 
Genomes AFR population). This finding further confirms 
the ability of the preferential LD approach to identify rarer 
and weakly tagged causal variants in a trans-ethnic setting.
DISCUSSION
In this study, we investigated the associations of 
74 breast cancer risk variants previously discovered by 
GWAS in 8,315 AA women from the AMBER consortium. 
We found that the majority of the GWAS-discovered 
variants identified from non-African populations could not 
be replicated in AA women in the AMBER consortium, 
which is consistent with the literature. Previously, Long 
et al. investigated 67 GWAS-discovered variants in 1,231 
AA cases and 2,069 controls, and found that only 10 of 
them (14.9%) were significantly associated (p<0.05) with 
overall breast cancer risk and by subtype. Chen et al. 
examined 19 risk variants identified by GWAS and Feng 
et al. further tested an additional 54 GWAS-discovered 
variants in AA women [53, 62]. Together, they showed 
that 12 of the 73 GWAS-discovered variants (16.4%) 
could be replicated in their study population of 5,761 
AA women at p<0.05. A recent large multi-consortium 
(including AMBER) fine-mapping study of breast cancer 
risk variants revealed that 10 of 73 (13.7%) tested GWAS 
hits were associated with breast cancer in 6,522 AA cases 
and 7,643 controls (under review, Haiman et al.). The 
consistently low replication rate from studies conducted 
by us and others [63, 64] reinforce the conclusion that it 
is challenging to extrapolate the GWAS variants identified 
from non-African populations to African ancestry 
populations, and highlight the challenge of trans-ethnic 
follow-up studies of GWAS hits.
Table 3: The 1000 Genome variants that passed study-wide significance when tested for association with breast 
cancer risk
rsIDa Position Neighboring 
Genes
Allele Frequency Imputation 
Quality
OR p-valueb Conditional 
p-valuec
Overall breast cancer risk
rs73731716 5:1298680 TERT, MIR4457 G 0.1073 0.9720 1.3123 1.33E-06 -
rs11668840 19:17399625 ANKLE1, ABHD8 C 0.4081 1.0679 0.8493 1.51E-06 -
rs8100241 19:17392894 ANKLE1 A 0.3980 1.0114 0.8476 2.29E-06 0.7897
rs12982058 19:17409380 ABHD8 T 0.3995 1.0130 0.8477 2.33E-06 0.7954
ER+ breast cancer risk
rs1112135 16:52639755 CASC16 T 0.3250 0.9996 1.2420 7.75E-07 -
rs4238750 16:52639236 CASC16 T 0.3250 1.0003 1.2417 7.90E-07 -
ER– breast cancer risk
rs11668840 19:17399625 ANKLE1, ABHD8 C 0.4132 1.0658 0.7589 1.49E-07 -
rs10069690 5:1279790 TERT T 0.5972 1.0313 1.3217 2.47E-07 -
rs61494113 19:17401859 ANKLE1, ABHD8 A 0.4019 0.9992 1.3153 2.51E-07 0.1068
rs12974508 19:17401521 ANKLE1, ABHD8 T 0.3983 1.0045 0.7594 4.10E-07 0.9825
rs12982058 19:17409380 ABHD8 T 0.4044 1.0129 0.7614 4.23E-07 0.7954
rs8100241 19:17392894 ANKLE1 A 0.4032 1.0099 0.7610 4.28E-07 0.7897
rs28473003 19:17406167 ABHD8 T 0.3443 0.9850 1.3092 9.79E-07 0.1241
a: the variants selected by the preferential LD approach are in bold.
b: the p-values were based on logistic regression between variant genotypes and breast cancer status while controlling for 
other covariates (see Methods).
c: p-value after conditioning on rs11668840.
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Besides sample size and statistical power, a number 
of additional factors could contribute to the low replication 
rate and therefore have direct influence on the trans-ethnic 
application of the preferential LD approach. First, the causal 
variants can be population specific [4, 14]. For example, 
the causal variants of nondiabetic end-stage renal disease in 
APOL1 gene are common in AAs but absent in European 
Americans [65]; the cardiomyopathy causal variant at 
Figure 2: Breast cancer association of variants within 500 kb of rs10069690 A. and rs2363956 B. in the AMBER cohort. The 
GWAS-discovered variants were denoted by the purple circles.
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Figure 3: Association between variants within 500 kb of rs3112572 and ER+ breast cancer A., between variants within 500 kb 
of rs10069690 B. and rs2363956 C. and ER- breast cancer in the AMBER cohort. The GWAS-discovered variants were denoted by the 
purple circles.
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Figure 4: Breast cancer association of variants within 500 kb of rs2981582 in the AMBER cohort. The GWAS-discovered 
variant rs2981582 is denoted by the purple circle. The -logP values before A. and after B. conditioning on the causal variant rs2981578 
were shown.
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MYBPC3 is common in individuals from South Asia but 
not observed elsewhere [66]; and the ABCA1 variant that 
reduces cholesterol efflux is Native-American ancestry 
specific [67]. As the GWAS-discovered variants, in general, 
are not the disease causing mutations but are linked to the 
causal variants, GWAS association signals resulting from 
a population-specific causal variant may disappear in 
other populations. Evidence is emerging that rare variants 
significantly contribute to cancer susceptibility including 
bladder cancer [23], ovarian cancer [19], glioma [27], 
prostate cancer [28, 29], and colorectal cancer [68–70]. 
As rare variants tend to be population specific, the cross-
population replication rate of GWAS findings in cancer 
is expected to be low. Second, even if the causal variants 
are identical across populations, they may have different 
effect size and allele frequencies [14]. For a replication 
population where the effect size or allele frequency of the 
causal variant is lower than in the discovery population, a 
much larger sample size is required to identify the same 
signal. Third, the tagging efficiency of the variants in the 
genotyping platform differs in populations [4, 5]. As has 
been seen in the FGFR2 locus, the GWAS-discovered 
variant in European population, rs2981582, is no longer a 
good proxy of the causal variant in AAs. With all of these 
considerations, well-powered breast cancer GWAS in 
African populations will not only improve the replication 
rate of the GWAS findings from other populations, but will 
also lead to identification of novel breast cancer loci that 
are specific to African ancestry. To date, there are only two 
moderately sized (~3,000 cases and ~3,000 controls) GWAS 
of breast cancer focused on women of African ancestry [40, 
41], indicating the under representation of this population. In 
addition, as most commercially existing genotyping arrays 
were designed with a focus on populations of European 
descent, the overall genomic coverage based on LD is 
reduced in other populations, especially in populations of 
African ancestry, which are known for increased genome 
diversity and decreased levels of LD [5]. Therefore, the 
causal variants in African populations may not be well-
captured using the existing genotyping platforms. Illumina 
has released its newly designed Infinium Multi-Ethnic 
Genotyping Array, which empowers GWAS studies in 
understudied populations including African-ancestry 
populations. Knowing that the GWAS signals exist in the 
populations of interest is essential to the success of follow-
up studies using the preferential LD approach.
For the 20 loci where the GWAS-discovered variants 
were replicated in AA women in the AMBER consortium, 
we applied the preferential LD approach to search for 
causal variant candidates or better markers for AA breast 
cancer risk. The preferential LD approach could identify 
better markers in 16 of the 20 loci, and in 13 of them, the 
approach could identify markers that were top 10 among 
all genotyped and imputed 1000 genomes variants in the 
corresponding locus, which indicates the ability of this 
approach to follow up GWAS hits trans-ethnically. The 
preferential LD approach was developed to identify causal 
variants by following the GWAS-discovered variants even 
if the causal variants are much rarer. It is important to 
note that the goal of the preferential LD is to follow up a 
particular GWAS signal to search causal variants driving 
the corresponding association instead of fine mapping a 
GWAS locus (eg. selecting variants based on LD pruning) 
where additional risk variants independent of the GWAS 
signal can exist. The success of this approach relies on two 
factors: the presence of the causal variant in the variant 
catalog used by the approach, and the GWAS-discovered 
variant being the best tag for the causal variant. However, 
there were limitations for both of these two assumptions 
in the current trans-ethnic study. First, the currently best 
publicly available variant resource for African Population 
is from the 1000 Genomes Project, which includes 246 
individuals of African-descent. As the causal variants of 
breast cancer are likely rare in the populations without 
breast cancer, they are expected to be depleted in this 
variant catalog, which was compiled from a relatively 
small number of healthy individuals. In our previous 
intra-ethnic application of the preferential LD approach, 
we utilized a comprehensive genome-wide variant catalog 
from 479 deeply sequenced individuals of European 
ancestry [15]. Being an understudied population, a 
comprehensive variant catalog is not readily available for 
populations of African descent. The recent availability 
of the extensive variant catalog from the UK10K project 
[71] and the Haplotype Reference Consortium [72] 
will significantly boost the genetic studies in European 
populations. The African Genome Variation Project 
(AGVP) [73] released recently and the Consortium on 
Asthma among African-ancestry Populations in the 
Americas (CAAPA) [74] are filling the gap for African 
populations. In contrast to CAAPA, the variants in AGVP 
were generated from genotyping and low-coverage 
sequencing and therefore rare variants may still be 
underrepresented in this dataset. Second, as described 
above, most of the GWAS-discovered variants in breast 
cancer were discovered in non-African population. Thus, 
the assumption of the GWAS-discovered variants being 
the best tags for the causal variants in African population 
is likely violated. Despite these limitations, we found that 
the preferential LD approach performed reasonably well in 
dissecting the GWAS signals in the AMBER consortium. 
Future studies with a more comprehensive variant catalog 
of African ancestry and the completion of well-powered 
breast cancer GWAS in African populations will be needed 
to better reveal the causal variants of breast cancer risk in 
AA women. In that case, the preferential LD approach can 
be directly carried out using the variant catalogs of AAs 
to follow up the AA GWAS-discovered variants, which 
is expected to be more powerful than the trans-ethnic 
application of this approach. On the other hand, given 
the promising trans-ethic performance of the preferential 
LD approach observed in this study, we anticipate more 
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and more trans-ethic application of this approach in other 
human traits to be carried out in the future, especially 
when GWAS in the population of interest is not available.
MATERIALS AND METHODS
The AMBER consortium
The AMBER Consortium [32, 33] was formed in 
2011 by combining data and biospecimens from four of 
the largest epidemiological studies of breast cancer in AA 
women: the Carolina Breast Cancer Study (CBCS) [42], 
the Women’s Circle of Health Study (WCHS) [43, 44], 
the Black Women’s Health Study (BWHS) [45] and the 
Multiethnic Cohort Study (MEC) [46].
The CBCS is a North Carolina population-based 
case control study of breast cancer. Breast cancer 
cases were identified using Rapid Case Ascertainment 
in cooperation with the NC Central Cancer Registry. 
Controls were identified using Division of Motor Vehicles 
lists for women under age 65 and Health Care Financing 
Administration lists for women 65 and older. The WCHS 
is a multi-site case control study in New York City (NYC) 
and New Jersey (NJ) aimed at evaluating risk factors for 
early and aggressive breast cancer in AA and European 
American (EA) women. Recruitment in NYC involved 
hospital-based ascertainment of cases, while controls were 
identified through random digit dialing (RDD). Cases in 
NJ were identified by the NJ State Cancer Registry using 
rapid case ascertainment. Controls were recruited though 
RDD and community-based efforts [47]. The BWHS is 
an ongoing prospective cohort study of health and illness 
among AA women, with a focus on cancer. Women 
diagnosed with breast cancer are identified by self-report 
in follow-up questionnaires, and confirmed by medical 
records, state cancer registries and the National Death 
Index. The MEC is a prospective cohort study that was 
designed to provide prospective data on cancer and other 
chronic diseases. Identification of incident breast cancer 
in study participants is by regular linkage with the Los 
Angeles County Cancer Surveillance Program and the 
State of California Cancer Registry. Controls in BWHS 
and MEC were chosen from among participants without 
breast cancer, and were frequency matched to cases on 
geographical region, sex, race, and 5-year age group.
All study participants provided consent for using 
their data and specimens for research purposes and the 
study was approved by Institutional Review Boards 
at participating institutions. ER status for cases was 
determined using pathology data from hospital records or 
cancer registry records.
Preferential LD approach
Our approach identifies candidate causal variants 
from a comprehensive variant catalog with four major 
steps [15]. First, we select variants that are: 1) in a 1 
Mb interval centered on a GWAS-discovered variant, 2) 
have not been evaluated in the GWAS of interest, and 
3) are rarer than the GWAS-discovered variant. Second, 
we identify the candidate variants that are preferentially 
tagged by the GWAS-discovered variant by calculating the 
preferential LD statistic, which estimates the percentage of 
all GWAS investigated variants that can tag the candidate 
variant better than or as well as the GWAS-discovered 
variant. Third, we perform permutation tests and keep 
the candidate variants that have non-random LD with 
the GWAS-discovered variant. Finally, we prioritize the 
candidate variants that are preferentially tagged by the 
GWAS-discovered variant and are functionally important 
on the basis of a sorting score that incorporates both the 
preferential LD statistic and evolutionary conservation. 
Candidate variants with statistically significant sorting 
scores are considered to be the candidates for causal 
variants driving the association between the GWAS-
discovered variant and the phenotype of interest.
We used the preferential LD approach to follow 
up the GWAS-discovered breast cancer risk variants that 
were replicated in the AMBER consortium by utilizing 
the variant catalog from the 1000 Genomes African 
population (phase I release 3). As the preferential LD 
approach excludes variants that were already interrogated 
in the corresponding GWAS from the search of candidate 
causal variants, we used the variants in the HapMap phase 
II YRI (Yoruba in Ibadan, Nigeria) samples as the variants 
analyzed for meta-GWAS, where multiple genotyping 
platforms and imputation were used, or when the GWAS 
platform content was unavailable (Supplementary Table 
S3). When assessing the performance of the preferential 
LD approach, we compared the candidate causal variants 
selected by our approach to all 1000 Genome variants 
that were in the 1Mb interval centered on the GWAS-
discovered variants and were available in the AMBER 
dataset.
Genotyping, quality control, and imputation
The GWAS-discovered variants and their 
corresponding followed-up variants selected by the 
preferential LD approach were added as part of the custom 
content to the Illumina Human Exome Beadchip v1.1 [48–
51], and genotyped in CBCS, WCHS, and BWHS by the 
Center for Inherited Disease Research (CIDR). Variants 
successfully genotyped were subjected to stringent quality 
control (QC) metrics. Variants that are monomorphic 
variants, failed CIDR technical filters, or had missing 
rate ≥ 2%, > 1 Mendelian error in 17 HapMap trios, or 
> 2 discordant calls between 192 duplicate samples were 
omitted. DNA from a total of 6,828 unique participants 
from CBCS, WCHS, and BWHS were successfully 
genotyped and passed sample-level QC, including 
removal of samples with missing rate ≥ 2% and samples 
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with unresolved identity. Variants from the 1000 Genomes 
project (Phase I v3, 11/23/2010) were imputed using 
SHAPEIT2 and IMPUTE2. In addition, 1528 AA subjects 
from MEC were previously genotyped with Illumina 
1M-Duo chip and imputed with the 1000 Genomes 
reference panel. The genotyped and imputed genotypes 
for the CBCS, BWHS, and WCHS were combined with 
the MEC data to generate a complete AMBER analytical 
dataset. Variants were excluded if the minor allele 
frequency (MAF) was less than 0.6%, the imputation info 
score (INFO) was less than 0.5 in either set, or if the allele 
frequencies between the two sets differed by > 0.15.
Statistical analysis
As principal component analysis (PCA) using 
variants genotyped in all four studies of the AMBER 
consortium revealed little heterogeneity across studies, 
we analyzed all studies jointly. PCA analysis identified 
35 population outliers. These outliers and six additional 
samples with missing phenotype information were omitted 
from association analyses. We used PLINK [52] to test 
the association between allelic dosage and susceptibility 
to breast cancer, ER+ breast cancer, and ER- breast 
cancer using logistic regression. Study, age, geographic 
location, DNA source, and principal components from the 
PCA analysis that had p-value <0.1 in the covariate-only 
models for the corresponding phenotype were included as 
covariates in the association models.
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